# [KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome

> **NCT05017844** · PHASE2,PHASE3 · COMPLETED · sponsor: **Kukje Pharma** · enrollment: 222 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** KSR-001-04
- **DRUG:** KSR-001-02
- **DRUG:** KSR-001-03

## Key facts

- **NCT ID:** NCT05017844
- **Lead sponsor:** Kukje Pharma
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-18
- **Primary completion:** 2021-02-08
- **Final completion:** 2021-06-22
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2021-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05017844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05017844, "[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT05017844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*